Amie Simmons

Cooley successfully secured the complete dismissal of a derivative action for FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease – as well as certain officers and directors. The case is In re FibroGen Inc. Derivative Litigation, C.A. No. 2022-0331-SG (Del. Ch.).

Cooley filed an amicus brief in the New York Court of Appeals on behalf of 47 corporate law professors in support of the continued application of the internal affairs doctrine.

Cooley successfully narrowed the class period, thereby substantially reducing the plaintiffs’ potential damages, in a securities class action against client FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease.

Cooley secured a win on behalf of BioMarin Pharmaceutical before the US Court of Appeals for the Ninth Circuit. The win affirmed a 2023 dismissal of a putative class action alleging violations of the Securities Exchange Act of 1934.

Cooley partnered with the Northern California Innocence Project to secure the release of Kevin Harper Jr., who was wrongfully convicted for the death of his infant son in 2008. Harper’s wrongful conviction, which resulted in a sentence of 25 years to life, was based on medical evidence that has since been widely discredited. A recent change in California’s AB 1540 law paved the way for the Sacramento District Attorney’s Office to re-review Kevin’s case. This allowed for a petition to resentence and release Harper, ending his 13-year incarceration in late January.